Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw unusually-high trading volume on Friday . Approximately 1,890,077 shares changed hands during mid-day trading, a decline of 16% from the previous session’s volume of 2,262,210 shares.The stock last traded at $93.40 and had previously closed at $89.03.

Several equities analysts have recently weighed in on BMRN shares. Credit Suisse Group AG restated a “buy” rating and set a $114.00 price objective (up previously from $103.00) on shares of BioMarin Pharmaceutical in a research report on Monday, June 13th. Oppenheimer Holdings Inc. restated a “market perform” rating and set a $99.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, April 6th. BMO Capital Markets started coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, April 7th. They set an “outperform” rating and a $99.00 price objective for the company. William Blair restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, March 22nd. Finally, Zacks Investment Research lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $122.96.

The stock has a 50 day moving average of $84.12 and a 200 day moving average of $84.06. The company’s market cap is $14.95 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, April 28th. The company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.32. During the same quarter last year, the firm earned ($0.43) EPS. The business had revenue of $236.70 million for the quarter, compared to the consensus estimate of $240.21 million. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical Inc. will post ($2.84) EPS for the current year.

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 550 shares of the business’s stock in a transaction that occurred on Monday, June 20th. The stock was sold at an average price of $82.77, for a total value of $45,523.50. Following the sale, the director now owns 13,860 shares in the company, valued at approximately $1,147,192.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Robert Ajer sold 415 shares of the business’s stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $86.03, for a total value of $35,702.45. Following the completion of the sale, the executive vice president now owns 63,487 shares in the company, valued at approximately $5,461,786.61. The disclosure for this sale can be found here.

A number of large investors have recently added to or reduced their stakes in the stock. ING Groep boosted its stake in BioMarin Pharmaceutical by 524.1% in the third quarter. ING Groep now owns 15,460 shares of the company’s stock valued at $1,628,000 after buying an additional 12,983 shares during the last quarter. I.G. Investment Management LTD. boosted its stake in BioMarin Pharmaceutical by 20.1% in the fourth quarter. I.G. Investment Management LTD. now owns 32,380 shares of the company’s stock valued at $3,392,000 after buying an additional 5,430 shares during the last quarter. Gulf International Bank UK Ltd boosted its stake in BioMarin Pharmaceutical by 0.9% in the fourth quarter. Gulf International Bank UK Ltd now owns 48,075 shares of the company’s stock valued at $5,036,000 after buying an additional 410 shares during the last quarter. GAM Holding AG boosted its stake in BioMarin Pharmaceutical by 60.4% in the fourth quarter. GAM Holding AG now owns 89,329 shares of the company’s stock valued at $9,358,000 after buying an additional 33,651 shares during the last quarter. Finally, TD Asset Management Inc. boosted its stake in BioMarin Pharmaceutical by 0.3% in the fourth quarter. TD Asset Management Inc. now owns 105,383 shares of the company’s stock valued at $11,040,000 after buying an additional 310 shares during the last quarter.

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.